InflaRx (IFRX)
(Delayed Data from NSDQ)
$0.80 USD
-0.01 (-1.83%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.80 0.00 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IFRX 0.80 -0.01(-1.83%)
Will IFRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IFRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IFRX
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
IFRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
Other News for IFRX
InflaRx reports Q2 EPS (21c) vs. (24c) last year
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | IFRX Stock News
InflaRx reports Q2 results
InflaRx to Report Second Quarter 2025 Results on August 7, 2025 | IFRX Stock News
InflaRx (IFRX) Faces Nasdaq Listing Challenge Due to Low Share Price | IFRX Stock News